Medical - Devices
Compare Stocks
4 / 10Stock Comparison
TIVC vs STIM vs ELMD vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Devices
Medical - Instruments & Supplies
TIVC vs STIM vs ELMD vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Diagnostics & Research | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $3M | $128M | $222M | $1.92B |
| Revenue (TTM) | $482K | $152M | $69M | $674M |
| Net Income (TTM) | $-8M | $-37M | $9M | $-173M |
| Gross Margin | -58.1% | 48.0% | 78.2% | 75.2% |
| Operating Margin | -15.5% | -19.4% | 16.7% | -27.2% |
| Forward P/E | — | — | 24.5x | — |
| Total Debt | $0.00 | $90M | $198K | $290M |
| Cash & Equiv. | $2M | $34M | $15M | $103M |
TIVC vs STIM vs ELMD vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Tivic Health System… (TIVC) | 100 | 0.0 | -100.0% |
| Neuronetics, Inc. (STIM) | 100 | 50.1 | -49.9% |
| Electromed, Inc. (ELMD) | 100 | 213.9 | +113.9% |
| NovoCure Limited (NVCR) | 100 | 16.2 | -83.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TIVC vs STIM vs ELMD vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TIVC plays a supporting role in this comparison — it may shine differently against other peers.
STIM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 99.2%, EPS growth 57.2%, 3Y rev CAGR 31.8%
- 99.2% revenue growth vs TIVC's -33.7%
ELMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.03
- 482.6% 10Y total return vs NVCR's 30.3%
- Lower volatility, beta 1.03, Low D/E 0.5%, current ratio 4.31x
- Beta 1.03, current ratio 4.31x
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 99.2% revenue growth vs TIVC's -33.7% | |
| Quality / Margins | 13.1% margin vs TIVC's -15.6% | |
| Stability / Safety | Beta 1.03 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +22.1% vs TIVC's -76.0% | |
| Efficiency (ROA) | 16.4% ROA vs TIVC's -173.3%, ROIC 25.6% vs -7.8% |
TIVC vs STIM vs ELMD vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TIVC vs STIM vs ELMD vs NVCR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ELMD leads in 4 of 6 categories
STIM leads 1 • TIVC leads 0 • NVCR leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ELMD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 1399.2x TIVC's $482,000. ELMD is the more profitable business, keeping 13.1% of every revenue dollar as net income compared to TIVC's -15.6%. On growth, ELMD holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $482,000 | $152M | $69M | $674M |
| EBITDAEarnings before interest/tax | -$7M | -$27M | $12M | -$165M |
| Net IncomeAfter-tax profit | -$8M | -$37M | $9M | -$173M |
| Free Cash FlowCash after capex | -$6M | -$4M | $9M | -$48M |
| Gross MarginGross profit ÷ Revenue | -58.1% | +48.0% | +78.2% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -15.5% | -19.4% | +16.7% | -27.2% |
| Net MarginNet income ÷ Revenue | -15.6% | -24.5% | +13.1% | -25.7% |
| FCF MarginFCF ÷ Revenue | -12.7% | -2.6% | +13.4% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.9% | +7.8% | +16.3% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +49.9% | +23.8% | +45.5% | -100.0% |
Valuation Metrics
STIM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3M | $128M | $222M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $599,551 | $184M | $207M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -3.12x | 31.23x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 24.48x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.43x | — |
| EV / EBITDAEnterprise value multiple | — | — | 19.14x | — |
| Price / SalesMarket cap ÷ Revenue | 3.34x | 0.86x | 3.47x | 2.92x |
| Price / BookPrice ÷ Book value/share | 116.77x | 4.62x | 5.42x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — | 20.06x | — |
Profitability & Efficiency
ELMD leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ELMD delivers a 19.8% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-2 for TIVC. ELMD carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to STIM's 3.44x. On the Piotroski fundamental quality scale (0–9), ELMD scores 7/9 vs TIVC's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.0% | -139.8% | +19.8% | -50.8% |
| ROA (TTM)Return on assets | -173.3% | -27.1% | +16.4% | -16.5% |
| ROICReturn on invested capital | -7.8% | -26.6% | +25.6% | -16.4% |
| ROCEReturn on capital employed | -180.0% | -28.5% | +22.0% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 7 | 5 |
| Debt / EquityFinancial leverage | — | 3.44x | 0.00x | 0.85x |
| Net DebtTotal debt minus cash | -$2M | $56M | -$15M | $187M |
| Cash & Equiv.Liquid assets | $2M | $34M | $15M | $103M |
| Total DebtShort + long-term debt | $0 | $90M | $198,000 | $290M |
| Interest CoverageEBIT ÷ Interest expense | — | -2.43x | — | -96.80x |
Total Returns (Dividends Reinvested)
ELMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ELMD five years ago would be worth $27,805 today (with dividends reinvested), compared to $1 for TIVC. Over the past 12 months, ELMD leads with a +22.1% total return vs TIVC's -76.0%. The 3-year compound annual growth rate (CAGR) favors ELMD at 34.7% vs TIVC's -83.3% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.5% | +27.8% | -1.9% | +28.3% |
| 1-Year ReturnPast 12 months | -76.0% | -59.6% | +22.1% | +1.1% |
| 3-Year ReturnCumulative with dividends | -99.5% | -16.4% | +144.6% | -75.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -86.7% | +178.1% | -91.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -93.4% | +482.6% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -83.3% | -5.8% | +34.7% | -37.6% |
Risk & Volatility
ELMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ELMD is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ELMD currently trades 87.4% from its 52-week high vs TIVC's 18.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.20x | 1.77x | 1.01x | 2.15x |
| 52-Week HighHighest price in past year | $5.60 | $4.85 | $30.73 | $20.06 |
| 52-Week LowLowest price in past year | $0.74 | $0.80 | $17.73 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +18.4% | +37.9% | +87.4% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 47.6 | 59.6 | 56.5 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 344K | 2.0M | 41K | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: STIM as "Buy", ELMD as "Buy", NVCR as "Buy". Consensus price targets imply 334.8% upside for STIM (target: $8) vs 41.5% for ELMD (target: $38).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $8.00 | $38.00 | $33.50 |
| # AnalystsCovering analysts | — | 7 | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.5% | 0.0% |
ELMD leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). STIM leads in 1 (Valuation Metrics).
TIVC vs STIM vs ELMD vs NVCR: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is TIVC or STIM or ELMD or NVCR a better buy right now?
For growth investors, Neuronetics, Inc.
(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus -33. 7% for Tivic Health Systems, Inc. (TIVC). Electromed, Inc. (ELMD) offers the better valuation at 31. 2x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TIVC or STIM or ELMD or NVCR?
Over the past 5 years, Electromed, Inc.
(ELMD) delivered a total return of +178. 1%, compared to -100. 0% for Tivic Health Systems, Inc. (TIVC). Over 10 years, the gap is even starker: ELMD returned +484. 2% versus TIVC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TIVC or STIM or ELMD or NVCR?
By beta (market sensitivity over 5 years), Electromed, Inc.
(ELMD) is the lower-risk stock at 1. 01β versus Tivic Health Systems, Inc. 's 2. 20β — meaning TIVC is approximately 118% more volatile than ELMD relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TIVC or STIM or ELMD or NVCR?
By revenue growth (latest reported year), Neuronetics, Inc.
(STIM) is pulling ahead at 99. 2% versus -33. 7% for Tivic Health Systems, Inc. (TIVC). On earnings-per-share growth, the picture is similar: Tivic Health Systems, Inc. grew EPS 88. 9% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, STIM leads at 31. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TIVC or STIM or ELMD or NVCR?
Electromed, Inc.
(ELMD) is the more profitable company, earning 11. 8% net margin versus -725. 0% for Tivic Health Systems, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELMD leads at 15. 1% versus -725. 8% for TIVC. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TIVC or STIM or ELMD or NVCR more undervalued right now?
Analyst consensus price targets imply the most upside for STIM: 334.
8% to $8. 00.
07Which pays a better dividend — TIVC or STIM or ELMD or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is TIVC or STIM or ELMD or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Electromed, Inc.
(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01), +484. 2% 10Y return). Tivic Health Systems, Inc. (TIVC) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +484. 2%, TIVC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TIVC and STIM and ELMD and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TIVC is a small-cap quality compounder stock; STIM is a small-cap high-growth stock; ELMD is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.